Lead by Marcela Maus, MD, PhD, the Cellular Immunotherapy Program brings together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.

Leadership

Marcela Maus

Marcela Maus, MD, PhD
Director, Cellular Immunotherapy Program, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School

Marcela Maus, MD, PhD, is Director of the Cellular Immunotherapy Program and a member of the Center for Cancer Immunology at Mass General. Her work aims to understand and engineer novel forms of cellular therapies – using cells normally produced by our bodies – to treat patients with cancer. Cellular therapies have achieved unprecedented, durable responses in some blood cancers, particularly CAR-T cell therapy in acute lymphoblastic leukemia. These results demonstrate the tremendous power of engineering the immune system to recognize and eliminate tumor cells, and effect long-term clinical benefit. However, to be able to harness this power of the cellular immune system in other cancers, there is a need to identify and validate new targets, and to develop ways of enhancing both the safety and effectiveness of imperfect targets. Dr. Maus is building the Cellular Immunotherapy Program to create new and improved treatments for patients with leukemia, myeloma and brain tumors initially, but hopes to expand the program over time to cover numerous tumor types.


Maus Laboratory

The goal of the Maus lab is to design and evaluate next generation genetically-modified (CAR) T cells as immunotherapy in patients with cancer. 


Clinical Investigators

To bring therapies to patients, a dedicated team of early-phase clinical investigators in oncology play a central role in cancer immunology at Mass General.

Jeremy Abramson

Jeremy Slade Abramson, MD
Director, Jon and JoAnn Hagler Center for Lymphoma
Mass General Cancer Center

 

 

Yi-Bin Chen

Yi-Bin Chen, MD
Director, BMT Program
Mass General Cancer Center

 

 

Amit Fathi

Amir Fathi, MD
Director, Center for Leukemia
Mass General Cancer Center

 

 

Justin Gainor

Justin F. Gainor, MD
Center for Thoracic Cancers
Mass General Cancer Center

 

 

Tim Graubert

Tim Graubert, MD
Director, Hematologic Malignancy Program
Mass General Cancer Center

 

 

Marcel Maus

Marcela Maus, MD, PhD
Director, Cellular Immunotherapy Program
Mass General Cancer Center

 

 

Noopur Raje

Noopur Suresh Raje, MD
Director, Center for Multiple Myeloma
Mass General Cancer Center

 

 

Ryan Sullivan

Ryan J. Sullivan, MD
Center for Multiple Myeloma
Mass General Cancer Center

 

 


Immune Monitoring Laboratory

The Immune Monitoring Laboratory is an essential and integral part of the Cellular Immunotherapy Program. The laboratory provides expertise to enable translational clinical studies of immune-based therapies, based on the highest standard operating systems.


Blood Transfusion Service

The Blood Transfusion Service is an FDA-licensed, full-service blood bank that consists of the Blood Donor Center, the Outpatient Infusion Unit, the Apheresis Unit, the Transfusion Service, and the Histocompatibility (HLA) Laboratory.

Robert Maker

Robert Makar, MD, PhD
Associate Director, Blood Transfusion Service
Massachusetts General Hospital

 


Cellular Therapy and Transplantation Laboratory

The Mass General Cancer Center’s Cellular Therapeutics and Transplantation Laboratory (CTTL) is comprised of a team of medical technologists that provide support to the Bone Marrow Transplant Program. These technologists play an integral part in stem cell processing, transplant infusions and bone marrow harvests.

Thomas Spitzer

Thomas Richard Spitzer, MD
CTTL Medical Director
Mass General Cancer Center